Remodelin
Based on 19 publication(s) in Google Scholar
Remodelin is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.84%
- CAS. Nr.: 949912-58-7
- Formel: C15H14N4S
- Molecular Weight:282.36
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Remodelin
More- Adv Sci (Weinh). 2025 Dec;12(46):e04245. [Abstract]
- J Hazard Mater. 2025 Oct 19:499:140193. [Abstract]
- Cell Death Dis. 2023 Nov 1;14(11):712. [Abstract]
- Acta Pharmacol Sin. 2023 Oct;44(10):2125-2138. [Abstract]
- Oncogene. 2021 Apr;40(15):2711-2724. [Abstract]
- Cell Rep. 2026 Jun 23;45(6):117408. [Abstract]
- Cell Rep. 2023 Jul 17;42(7):112810. [Abstract]
- J Agric Food Chem. 2022 Jan 12;70(1):403-414. [Abstract]
- Life Sci. 2023 Oct 1:330:121948. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- iScience. 2025 Jun 9;28(7):112860. [Abstract]
- J Virol. 2024 Jan 23;98(1):e0135023. [Abstract]
- Heliyon. 2023 Jun 8;9(6):e17103. [Abstract]
- Epigenetics. 2024 Dec;19(1):2417158. [Abstract]
- bioRxiv. 2026 Jun 19.
- bioRxiv. 2026 Jan 14.
- bioRxiv. 2025 Sep 1:2025.09.01.673489. [Abstract]
- SSRN. 2025 Jul 28.
- bioRxiv. 2023 Feb 11.
-
WB
-
IHC
-
IHC
-
WB
-
Apoptosis Analysis
Biologische Aktivität
|
NAT10 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BTI-TN-5B1-4 | IC50 |
221 nM
Compound: 9
|
Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay
Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay
|
[PMID: 20579890] |
| BTI-TN-5B1-4 | IC50 |
644 nM
Compound: 9
|
Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay
Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay
|
[PMID: 20579890] |
Remodelin (10-40 μΜ, 1-7 days) inhibits NAT10 activity and cell proliferation with a dose-dependent manner in both AR-positive and AR-negative prostate cancer cells[2].
Remodelin (20 μΜ, 24 hours) inhibits NAT10 and slows DNA replication in prostate cancer cells[2].
Remodelin (1 μΜ, 7 days) decreases nuclear shape defects and increase genomic stability in LmnaG609G/G609G fibroblasts[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Prostate cancer cell lines VCaP, PC3, and DU145
-
Concentration:0,10,20,40 μM
-
Incubation Time:1,2,7 days
-
Result:Inhibited NAT10 and suppressed the growth of both AR-positive and AR-negative prostate cancer cells.
Displayed significantly decreased cell proliferation activity over time, compared to the control group.
Decreased colony formation ability with a dose-dependent manner.
-
Cell Line:Prostate cancer cell lines VCaP, PC3, and DU145
-
Concentration:0,10,20,40 μM
-
Incubation Time:24 hours
-
Result:Showed a significant decrease in both the positive labeling rate and the fluorescence intensity compared to the control group.
Significantly reduced both the staining foci of IdU and the staining foci of CldU compared to control group.
-
Cell Line:Skin fibroblasts from LmnaG609G/G609G and wildtype (WT) littermates
-
Concentration:1 μM
-
Incubation Time:7 days
-
Result:Decreased the higher level of the DNA double-strand break (DSB) marker gamma H2AX (γH2AX, Ser-139 phosphorylated histone H2AX).
Remodelin (100 mg/kg, p.o.) inhibits NAT10 and significantly enhances the healthspan in aLmnaG609G/G609G hutchinson-gilford progeria syndrome (HGPS) mouse model. Remodelin (5 mg/kg, p.o.) shows a T1/2 of 1.81 hours and oral bioavailability (F%) of 43.5% in mice[3].
Pharmacokinetic parameters for Remodelin in Mice[1]
| Route | Dose (mg/kg) | T1/2 (h) | Tmax (h) | Cmax (ng/mL) | AUC0-t (ng/h/mL) | AUC0-Ꝏ (ng/h/mL) | MRT_last (h) | F(%) |
| p.o. | 5 | 1.81 | 0.25 | 409 | 235 | 259 | 0.84 | 43.5% |
| Route | Dose (mg/kg) | T1/2 (h) | Tmax (h) | Cmax (ng/mL) | AUC0-t (ng/h/mL) | AUC0-Ꝏ (ng/h/mL) | MRT_last (h) | F(%) |
| p.o. | 5 | 1.81 | 0.25 | 409 | 235 | 259 | 0.84 | 43.5% |
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5416 mL | 17.7079 mL | 35.4158 mL | 88.5395 mL |
| 5 mM | 0.7083 mL | 3.5416 mL | 7.0832 mL | 17.7079 mL | |
| 10 mM | 0.3542 mL | 1.7708 mL | 3.5416 mL | 8.8539 mL | |
| 15 mM | 0.2361 mL | 1.1805 mL | 2.3611 mL | 5.9026 mL | |
| 20 mM | 0.1771 mL | 0.8854 mL | 1.7708 mL | 4.4270 mL | |
| 25 mM | 0.1417 mL | 0.7083 mL | 1.4166 mL | 3.5416 mL | |
| 30 mM | 0.1181 mL | 0.5903 mL | 1.1805 mL | 2.9513 mL | |
| 40 mM | 0.0885 mL | 0.4427 mL | 0.8854 mL | 2.2135 mL | |
| 50 mM | 0.0708 mL | 0.3542 mL | 0.7083 mL | 1.7708 mL | |
| 60 mM | 0.0590 mL | 0.2951 mL | 0.5903 mL | 1.4757 mL | |
| 80 mM | 0.0443 mL | 0.2213 mL | 0.4427 mL | 1.1067 mL | |
| 100 mM | 0.0354 mL | 0.1771 mL | 0.3542 mL | 0.8854 mL |